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Abstract
Poly (ADP-ribose) polymerase-1 (PARP1) is a nuclear enzyme involved in DNA repair,
chromatin remodeling and gene expression. PARP1 interactions with chromatin architec-
tural multi-protein complexes (i.e. nucleosomes) alter chromatin structure resulting in
changes in gene expression. Chromatin structure impacts gene regulatory processes
including transcription, splicing, DNA repair, replication and recombination. It is important to
delineate whether PARP1 randomly associates with nucleosomes or is present at specific
nucleosome regions throughout the cell genome. We performed genome-wide association
studies in breast cancer cell lines to address these questions. Our studies show that
PARP1 associates with epigenetic regulatory elements genome-wide, such as active his-
tone marks, CTCF and DNase hypersensitive sites. Additionally, the binding of PARP1 to
chromatin genome-wide is mutually exclusive with DNA methylation pattern suggesting a
functional interplay between PARP1 and DNAmethylation. Indeed, inhibition of PARylation
results in genome-wide changes in DNA methylation patterns. Our results suggest that
PARP1 controls the fidelity of gene transcription and marks actively transcribed gene
regions by selectively binding to transcriptionally active chromatin. These studies provide a
platform for developing our understanding of PARP1’s role in gene regulation.
Introduction
Chromatin, comprising repeating units of nucleosomes, plays a vital role in gene expression by
regulating the access of regulatory proteins to their target binding sites. This access is con-
trolled by the locations of nucleosomes along genomic DNA. Interestingly, nucleosome posi-
tions are controlled by various factors including DNA sequence [1–4], incorporation of histone
variants, histone posttranslational modifications, DNAmethylation and chromatin
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Data Availability Statement: PARP1-ChIP-seq and
PARylation-mediated methylation data have been
deposited in GEO with accession numbers
GSE61744 and GSE61916 respectively. PARP1
correlation calculations: For all of the correlation
calculations, the values obtained in each window
were transformed by log10 (value + 1). For each
pairwise correlation, only those windows where both
transformed data values were present were used for
analyses. All of the code used in the correlation
analysis is available in the
fmcorrelationbreastcaparp1 R package available from
architectural proteins (CAPs) [5]. The complex molecular mechanisms through which chro-
matin binding proteins, DNA sequence, and histone modifying enzymes coordinate to alter
chromatin structure and function to regulate gene expression require more focused study to
elucidate their specific interplay.
In this study, we aimed to determine the genome-wide functional location of Poly (ADP-
ribose) Ribose Polymerase-1 (PARP1) also known as ADP-ribosyl transferase1 (ARTD1), an
NAD-dependent chromatin-associated protein. PARP1 is widely known for its role in DNA
repair and cell death [6,7]. Recent studies have now extended the physiological roles of PARP1
to include regulation of gene expression at both the transcriptional and splicing levels [8–10].
These studies suggest that PARP1 affects gene expression via its chromatin remodeling activity
[11,12]. Several possible mechanisms exist through which PARP1 could regulate chromatin
structure. First PARP1 binds at the entry/exit sites between the nucleosome and linker DNA
[13] and may influence spontaneous nucleosome opening [14,15] thereby allowing access to
DNA by regulatory proteins [16–18]. Second, as a chromatin remodeler, PARP1 PARylates
core histones, linker histone H1 and chromatin architectural proteins (CAPs) such as histone
H1 and HMGN1 [19–24]. Third, PARP1 competes with histone H1 for binding to nucleo-
somes [25]. All of these activities result in changes to chromatin structure and gene regulation.
Although PARP1 undergoes auto-PARylation during transcriptional activation, several tran-
scription repressor complexes undergo PARylation followed by dissociation from gene pro-
moters [26], resulting in gene repression. These studies therefore implicate PARP1 both in
transcriptional repression and activation.
Indeed PARP1 is found both at silenced [27] and activated genomic loci [25,28,29]. PARP1
modifies histones, recruits and modulates the activity of histone variants [22,27,28] and remo-
delers [21], and disrupts nucleosomes [24,30,31]. To begin to decipher the mode of action of
PARP1 in transcription regulation, it is imperative to profile PARP1’s functional genome-wide
location. In this study we carried out nucleosome ChIP-seq experiments to determine the func-
tional location of PARP1-bound nucleosomes in human cells. We found that PARP1 is associ-
ated with active histone modifications and is bound to regulatory regions. PARP1’s role in
gene regulation may be explained through an active competition of PARP1 chromatin binding
and DNA methylation. We performed additional genome-wide methylation analyses, which
showed changes in methylation patterns resulting from inhibition of PARylation. These studies
demonstrate an intricate reciprocal interplay between PARP1 and DNAmethylation, provid-
ing a platform to delineate PARP1’s functional role. We explore this role in two cancerous
model cell lines that respond differently to PARP1 inhibitors.
Materials and Methods
Cell culture and nuclei isolation
MDA-MB231 and MCF7 cells were cultured in DMEM (Invitrogen) supplemented with 10%
FBS (Hyclone). 100 x 106 cells were cross-linked with 1% formaldehyde at RT for 10 min. The
cross linking reaction was stopped with 125 mM glycine. Cells were then lysed in NP-40 hypo-
tonic lysis buffer (10 mM Tris [pH 7.4], 10 mMNaCl, 3 mMMgCl2, 0.5% NP-40, 0.15 mM
spermine, 0.5 mM spermidine, complete protease inhibitor cocktail) for 30 minutes followed
by dounce homogenization.
SiRNA treatment of cells. siRNA targeting the coding sequence of β-galactosidase (LacZ)
was used as a non-specific control. SiRNAs against human PARP1 (ON-TARGETplus) from
Thermo Scientific Dharmacon and transfection was performed as per the manufacturer using
Dharmafect reagent 2.
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GitHub (https://github.com/rmflight/
fmcorrelationbreastcaparp1) [45]. The data used in
the correlation analyses are available as RData files
for download from figshare (http://figshare.com/
articles/FM_Parp1_Correlation_Data/1266451) [50]
and the code and steps used in transforming the data
are available in fmdatabreastcaparp1 R package on
GitHub (https://github.com/rmflight/
fmdatabreastcaparp1) [49].
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Treatment of cells with Aza-cytidine: Cells were treated with 1 μM aza-cytidine for 2 days.
Water treated growth match controls were used. In all the experiments, cell viability was deter-
mined using trypan blue exclusion test while apoptosis was measured with the Annexin V-PI
kit according to the manufacturer's protocol (Trevigen).
Treatment of cells with PJ34 treatment. Cells were treated with PJ34 similar to Krishna-
kumar et al, 2010 [29], with slight modification–to ensure complete effect of PARylation inhi-
bition, cells were treated with 5 μM PJ34 overnight (~16 hours).
Treatment of cells DPQ. MCF7 cells at 70% confluency were treated with 10 μM
3,4-Dihydro-5[4-(1-piperindinyl0butoxy]-1(2H)-isoquinoline (DPQ) or overnight for about
16 hours, an equal volume of DMSO was used for control.
Nucleosome-Chromatin Immunoprecipitation (nuc-ChIP)
ChIP was performed as described by [32,33] with minor modifications. Chromatin was cross-
linked with 1% final formaldehyde concentration for 8 min at room temperature. Cross-linking
was stopped by a final concentration of 0.125 M glycine incubated for 5 min at room tempera-
ture on a rocking platform. The medium was removed and the cells were washed twice with
ice-cold PBS. Cells were lysed by incubating for 5 mins in cold lysis buffer (1% SDS, 10 mM
EDTA, protease inhibitors, 50 mM Tris–HCl, [pH 8]). Resulting nuclei were washed in MNase
buffer (10mM Tris [pH 7.4], 15mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM spermi-
dine, 2 mM CaCl2). Chromatin was subjected to micrococcal nuclease (MNase) digestion, with
pre-determined MNase concentration, in MNase buffer at RT to yield nucleosomal fragments
with less than 3 nucleosomes (~450 bp). 25 mM EDTA and 0.2% SDS was used to stop the
reaction and sample was centrifuged to remove cellular debris. Lysates were diluted 1:10 in
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mMNaCl, protease
inhibitors, 16.7 mM Tris–HCl, [pH 8]). Non-specific background was removed by incubating
the MNase digested chromatin with dynabeads (Invitrogen) overnight at 4°C with rotation in
the presence of BSA (250 μg/ml). Precleared chromatin solutions were incubated overnight at
4°C with rotation with antibodies against PARP1 (#39559, Active Motif) and for control, IgG.
The immuno-complexes were collected with 200 μl of MagnaChIP protein A beads (Millipore)
for 3 h at 4°C with rotation. The beads were washed sequentially for 3 min by rotation with 1
ml of the following buffers: low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
150 mMNaCl, 20 mM Tris–HCl, [pH 8]), high salt wash buffer (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 500 mMNaCl, 20 mM Tris–HCl, pH 8.1) and LiCl wash buffer (0.25 M LiCl, 1%
Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris–HCl, [pH 8]). Finally, the
beads were washed twice with 1 ml TE buffer (1 mM EDTA, 10 mM Tris–HCl, [pH 8]). The
immuno-complexes were then eluted by adding 500 μl of elution buffer (25 mM Tris–HCl,
[pH 7.5], 10 mM EDTA, 0.5% SDS) and incubating for 60 min on rotation. The cross-linking
was reversed at 65°C and the remaining proteins were digested with 80 μg/ml proteinase K
(Fermentas) and incubating overnight at 65°C. The DNA was recovered by purifying with Qia-
gen PCR purification kit. Immunoprecipitated chromatin DNA was then run on a 3.3%
Nusieve gel. Mononucleosomal fragments were cut from the gel and adapted for deep-sequenc-
ing as we described previously [34]. For ChIP-qPCR experiments, eluted samples were used for
quantitative real-time PCR or normal PCR. For MNase-seq analyses, experiments were per-
formed as we had previously done [35].
Preparation of ChIP-seq libraries
Sequencing libraries were prepared with the SOLiD ABI technologies as previously described
[36]. Briefly: ChIPped mononucleosomal DNA was gel purified, ligated with the adapters and
Functional Location of PARP1-Chromatin Binding
PLOS ONE | DOI:10.1371/journal.pone.0135410 August 25, 2015 3 / 22
then PCR amplified with SOLiD primers for 10 cycles. PCR product, corresponding to mono-
nucleosomal DNA, was gel purified and loaded onto a SOLiD flow cell for cluster generation
and genome-wide sequencing.
Data Analyses
PARP1 colorspace fasta reads were converted to basespace fastq format by the Northwestern
University Genomics core using a custom script. We sorted PARP1 reads into separate library
files based on their barcodes, and mapped the reads to the human genome (hg19) using bowtie
v2 with the default parameters allowing for two mismatches [37]. Unique reads with zero or
one mismatch were considered for further analysis. Amplification bias was removed by filter-
ing more than two copies of redundant reads that come from the same locus. We compared
how well technical replicates within each cell of PARP1 binding overlapped each other. The
degree of overlap among peak-sets for all two biological replicates was more than 75%, demon-
strating a high level of reproducibility (S1A Fig) further confirmed with a Pearson correlation
of r> 0.823; p< 10−16 (S1B Fig). Because of this high reproducibility between the replicates,
the unique reads were combined and reanalyzed to produce composite binding regions. A total
of 54,125,493 and 60,486,178 non-redundant uniquely mapped reads were obtained for MCF7
and MDA-MB231 cells respectively.
Defining PARP1 binding sites. Two different methods were used to analyze PARP1
binding regions since no peak-calling program has gained consensus acceptance by the scien-
tific community as the preferred tool for ChIP-Seq data analysis [38].
First method: The mean nucleosomal fragment length of each library was estimated by com-
puting the offset yielding the highest covariation of read depth between the forward and reverse
strands. The PARP1 nucleosome midpoint locations were estimated as the read start plus the
offset (or minus the offset for those mapping to the reverse strand). Next we estimated the dis-
tribution of fragment sizes from separation of read pairs, and discarded read pairs outside of
the central 95% of distribution (101–191 bp). Finally we estimated nucleosome midpoints as
the midpoint between read pairs.
Second method: MACS (Model-based Analysis for ChIP-Seq) was used to identify peaks
from the ChIP-Seq data and therefore determine PARP1 binding sites. For each replicate,
peaks were identified with a default p-value significance of 1x10-5. ChIP-Seq peaks were
detected using Macs2 [39,40] with the broad option and a window size of 200 bp. Overlaps
between each ChIP-Seq data peaks (CTCF, histone modifications and PARP1 replica) and
PARP1 peaks were determined by using an overlap of at least 10% of the ChIP-Seq peak with
the PARP1 peak. MNase-seq data was used as ‘input’ control in calling PARP1-peaks.
Both methods yielded very similar results, while having different limitations: method 1 pro-
duces background noise and method 2 possibly eliminated PARP1 binding sites,.
In order to visualize PARP1-bound nucleosome tag-density across the human chromo-
somes on the UCSC browser for hg19, ready-to-visualize bedgraph files were created using the
HOMER package v3.13 [41]. Briefly, aligned reads were extended to the average fragment size
(~160 bp) and read coverage on each base across the genome was calculated. Read coverage
was then scaled to one million and normalized with the total number of reads. All publicly
available data used for pairwise comparisons with our PARP1 data were processed in the same
way. We also used total nucleosome (nucleosome-seq) data to normalize for background
correction.
We conducted a Gene Ontology analysis using the Database for Annotation, Visualization,
and Integrated Discovery (DAVID) [42] on genes with a PARP1 peak within 1 kb of the TSS as
determined by MACS (P< 10−5) or by our method.
Functional Location of PARP1-Chromatin Binding
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Correlations with DHS and CTCF sites: A list of previously identified CTCF sites for MCF7
cells [43,44] was obtained (UCSCModEncode database), and the correlations of PARP1 and
CTCF binding was calculated using a custom script (figshare [45]). A Similar procedure was
applied to align PARP1 ChIP-Seq data with DNase hypersensitive sites (DHS) using DHS data
from UCSC genome database [46,47]. These analyses were performed at TSSs as well as in 2 kb
windows across the genome, providing genome-wide information.
Correlations with histone modifications: ChIP-Seq data for the various histone modifica-
tions in MCF-7 cells were downloaded from the UCSC ENCODE data portal [48]. We took 2
kb windows surrounding all annotated TSSs and computed mean values for each histone modi-
fication experiment in each window. For the same windows, we also computed normalized val-
ues for the PARP1 experiments by dividing the number of midpoints from a given experiment
by the number total nucleosome midpoints and taking the log. We then computed Pearson R
correlations across windows for all possible pairs of experiments. Similarly we divided the
genome into 2 kb windows and measured the correlation. Custom script is available in figshare
[45,49–51].
Mapping PARP1 signals across high and low expressed gene TSS: PARP1 ChIP-Seq tags
from both cell lines were aligned with TSS coordinates from Ensembl transcript of high and
low expressed gene RNA-Seq data [52]. PARP1 nucleosomal reads were mapped to +/- 1000
bp surrounding known TSS using a 5 bp sliding window. These 2 kb windows were generated
across the human genome (genome wide) using the tileGenome function from the Genomi-
cRanges package [53] and the BSgenome.Hsapiens.UCSC.hg19 package (BSgenome.Hsapiens.
UCSC.hg19 1.3.1). Mapped reads were normalized to total reads in each ChIP-Seq data set.
Since TSS data has a strand option, end number position was used for negative strand, whereas
positive number position was used for a positive strand to match against the same strand and
chromosome from our ChIP-Seq libraries. We computed the Pearson correlation between gene
expression and the density of PARP1 and nucleosome midpoints (center) density in each
region.
Real-Time qPCR (qPCR)
ChIP was performed on MNase digested chromatin fragments as before using anti-PARP1
antibodies. 6 μg of antibody, 100 μl of dyna beads and 400 μg of chromatin were used for each
ChIP. IgG was used as a no-antibody control. Antibody bound (IP) chromatin DNA along
with no-antibody control was analyzed by qPCR using the PerfeCTa SYBR Green FastMix
(Quanta Biosciences Inc, USA) and C1000 Thermal Cycler (Bio-Rad, USA) following the man-
ufacturer's instructions. The primers used to amplify the selected gene promoters were as fol-
lows: IGFBP6: Forward 5’-ccaccacaatgctagggtct-3’, Reverse 5’-cagactggggtaagccaatg-3’;
IGFBP7: Forward 5’-ggcaacggtttgtcctttta-3’, Reverse 5’-aaaacccccacttgtggact-3’. 20 μl reactions
was set up using 1 μl of ChIP DNA, 10 μl of 2x PerfeCTa SYBR Green FastMix and 0.5 μM
each of gene specific primers. The cycling conditions were: 95°C for 2:00 m; 40 cycles of 95°C
for 30 s, 55°C for 30 s and 72°C for 1:00 m. Fluorescence was measured right after each elonga-
tion step. Dissociation curves were used to confirm specificity of PCR products. “Signal over
background” normalization method was used to calculate fold enrichment [54].
Analysis of PARP1 functional binding at homo- and hemi-methylated
CpG and non CpG sites
Genome-wide methylation profiles of CpG and non-CpG (CWG) sites in MDA-MB231 cells
were obtained from NGSmethDB [55] database. The total number of methylated reads at each
location was calculated as the number of aligned reads multiplied by the percentage of those
Functional Location of PARP1-Chromatin Binding
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reads that were methylated. This total number of methylated reads was summed for each 2 kb
window. The binding profiles of PARP1 at methyl CpG and CWG sites were created by align-
ing the above genome-wide methylation profiles with PARP1 ChIP-Seq libraries. The ratio of
the number of PARP1 ChIP-Seq reads found in a 2 kb region centered on the methyl CpG or
CWG site over the mean number of PARP1 ChIP-Seq reads found throughout the genome
were plotted. A similar procedure was used to align histone modification profiles with PARP1
ChIP-Seq libraries using genome-wide histone modification date generated [56,57].
DNA sample preparation, bisulfite conversion and methylation level measurement: DNA
was extracted from experimental samples using the Genomic DNeasy kit (Qiagen), as
described by the manufacturer. DNA quantification was performed using a nanodrop. 750 ng
of the DNA was used as input for the bisulfite conversion using the Zymo EZ-96DNAMethyla-
tion Kit (Catalog #D5004) Deep-Well Format. Then 4 ul of the bisulfite converted DNA was
used as input for the Illumina Infinium HDMethylation Assay and performed per Illumina’s
standard protocol. Processed methylation chips were scanned using an iScan reader (Illumina).
Paired samples (vehicle-treated and corresponding PJ34-treated samples) were processed on
the same chip, and all samples were processed at the same time to avoid chip-to-chip variation.
Data quality control and preprocessing: Infinium methylation data were processed using
the Methylation Module of the GenomeStudio software package (v. 2011.1). Target success
rate was determined. The detection p-value is the 1-p computed from the background model
characterizing the chance that the target sequence was distinguishable from the negative con-
trols. For quality control, methylation measures with a detection p-value>0.05 and samples
with a CpG coverage<95% were removed. Ultimately all samples passed the coverage criteria.
The data were initially normalized using internal controls in the GenomeStudio software. Sam-
ple replicates and Jurkat control replicates were checked to ensure an r2 value>0.99.
Determination of differential methylation patterns: The methylation levels of CpG sites
were calculated as β-values (β = intensity (methylated) / intensity (methylated + unmethy-
lated)). A non-normal distribution of DNAmethylation within each sample was observed.
Therefore, a non-parametric method, paired two-sample Wilcoxon signed-rank test was per-
formed to assess the differences in global DNA methylation between the treated and non-
treated samples. To assess the difference of DNA methylation level between the treated and
untreated samples at a single CpG site, the absolute value of the log2 fold change was calculated.
CpGs are considered differentially methylated if the absolute value of the log2 fold change is
greater than one. A hypermethylated CpG site is observed if the DNA methylation level is
higher in the treated sample; a hypomethylated CpG site is observed if the DNA methylation
level is higher in the untreated sample. The data were further normalized using a peak correc-
tion algorithm embedded in the IMA-R package.
DNA isolation and MSRE-PCR: Genomic DNA was isolated from cells using DNeasy kit
(Qiagen). About 1 μg of genomic DNA was digested at 37°C for 8 hours with 20U ofHindIII
and further digested with overnight with 20U of methylation sensitive enzymesHhaI and
HpaII (NEB). All restriction enzymes were from New England Biolabs. DNA was purified
using Qiagen PCR purification kit and used for PCR analyses. PCR amplification was per-
formed using Taq DNA polymerase (Invitrogen). The PCR conditions were 95°C for 5 min fol-
lowed by 35 cycles at 95°C for 45 s, 60°C for 45 s, 72°C for 1 min and a final extension of 72°C
for 10 min. MethPrimer [58] was used for primer design; primer sequences are available upon
request.
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Results
PARP1 binds to promoters of active genes
To determine the genome-wide location of PARP1, we carried out nucleosome-chromatin
immunoprecipitation followed by deep-sequencing (nuc-ChIP-seq) in the human cell lines
MCF7 and MD-MB231 [59]. Following nucleosome-ChIP analysis, the DNA fraction of the
eluted ChIP sample was run on a 3.3% nusieve agarose gel (S2A Fig). Western blot analyses
confirmed the eluted fraction contained PARP1 bound nucleosomal fragments (S2B Fig). The
mononucleosomal DNA fragment was then excised from agarose gel and subjected to paired-
end deep-sequencing. After sequencing, we aligned the reads to the human genome (HuRef-
Hg19) and discarded non-unique reads. Two to three replicas that showed reproducibility
from each cell line were used to build a composite binding data set for PARP1. A total of 5–6 X
107 paired-end reads were retained for PARP1-bound nucleosomes in MCF7 and
MDA-MB231 cells, respectively. This corresponds to ~4 fold coverage if every nucleosome is
PARP1-bound. However, since PARP1 binds selectively, we believe the coverage to be even
higher. We then used these reads to determine the functional location of PARP1-bound nucle-
osomes. The number of PARP1-ChIP-seq nucleosome centers within each region was counted
and divided by the total number of mapped reads to estimate the relative abundance of
PARP1-bound nucleosomes per genomic region.
To determine the functional binding of PARP1 genome-wide, we analyzed its binding to
key gene regulatory regions. We showed recently in Drosophila cells that PARP1 binds to active
promoters (Matveeva et al., 2015—submitted), corroborating earlier lower resolution data in
human MCF7 [25]. We therefore asked whether this is true in human cell lines using the higher
resolution analyses obtained with nuc-ChIP-seq. For this, we assayed for PARP1-nucleosome
binding sites within 1 kb of transcription start sites (TSSs). Only genes with some evidence for
expression (>0 RNA-seq signal) were used. We called genes low or high expression if they fell
into the lower or upper quartiles of these genes. In total, 4985 low expression TSSs and 5196
high expression TSSs were used. Generally, PARP1 occupied promoters of highly expressed
genes (upper quartile of expressed genes) and was absent at the promoters of repressed genes
(bottom quartile of expressed genes) both in MCF7 (Fig 1A) and MDA-MB231 cells (Fig 1B).
To further test the correlation between PARP1 binding and gene expression, we divided gene
activity into 10 deciles based on the level of gene expression. For this analysis we counted the
number of midpoints in the region from -500 to +250 around the TSSs. Here too, we observed
that the higher the gene expression levels, the more binding of PARP1 to the promoters of
these genes (Fig 1C and 1D), suggestive of an association of PARP1 with gene activity.
We tested and validated our results from nuc-PARP1-ChIP-seq using ChIP followed by
quantitative real time PCR at two PARP1-binding representative genes. When comparing the
IGFBP7 and IGFBP6 gene promoters in MDA-MB231 cells to MCF7 cells, we observed higher
PARP1 occupancy signals (S3A and S3B Fig). To validate the binding of PARP1 to active pro-
moters, we measured the relative PARP1 occupancy at active promoters in the two cell types.
The ChIP-qPCR results confirm our nuc-ChIP-seq data (S3C and S3D Fig). Interestingly,
IGFBP7 and IGFBP6 are both expressed in MDA-MB231 cells and not in MCF7 cells [60–62]
(S3E Fig). Additionally knockdown of PARP1 (S4A and S4B Fig), showed a depletion of
PARP1 occupancy at 3 PARP1-target sites as measured by qPCR (S4C and S4D Fig). Together,
our results show a positive correlation between PARP1 enrichment at promoter regions and
the level of gene expression: the higher the gene expression the more the enrichment of
PARP1. These observations are in line with lower resolution studies that show PARP1 binds to
active gene promoters [24,25].
Functional Location of PARP1-Chromatin Binding
PLOS ONE | DOI:10.1371/journal.pone.0135410 August 25, 2015 7 / 22
PARP1 associates with distinct histone marks and DNase I
hypersensitive sites
Gene expression is associated with the presence of different types of histone marks present at
the promoters of genes. H3K36me3, H3K4me3, and H3K27ac are considered “active”marks,
whereas H3K9me3 and H3K27me3 are considered “repressive”marks [63]. We therefore
asked whether the binding of PARP1 correlated with the presence of particular histone marks.
ChIP-seq reads of various histone marks were obtained [48] and used to correlate the binding
of PARP1 to genomic regions containing these histone marks. Using 2 kb windows around
annotated TSSs, we computed the mean signal for each histone PTM and estimated the density
of PARP1-bound nucleosomal reads. We found that PARP1 associated with the activating his-
tone PTM H3K4me3, and with the elongating mark H3K36me3 (Fig 2A). On the other hand,
PARP1 associated neither with regions containing the activating mark H3K27ac nor with the
repressive heterochromatin marks H3K9me3 and H3K27me3. We further quantified the corre-
lation of PARP1 and histone PTMs genome-wide (S1 Table) and observed a moderate positive
Pearson correlation with H3K4me3 at TSSs of r = 0.357 (p = 0.4e-16) and r = 0.3447 (p< 0.5e-
Fig 1. PARP-1 binds promoters of active genes.Midpoints of the reads of PARP1-associated nucleosomes were plotted against distance from TSSs.
PARP-1 associates with highly transcribed gene TSS’s (solid red line), and not with promoters of low expressed or repressed gene promoters (solid blue) in
(A) MCF7 cells and (B) MDA-MB231 cells. All genes were ranked by level of expression in both MCF7 and MDA-MB231 cells and sorted into deciles from
lowest to highest. Mapping of PARP1 association show increased PARP-1 enrichment at TSS as level of gene expression increases in (C) MCF7 and (D)
MDA-MB231 cells.
doi:10.1371/journal.pone.0135410.g001
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16) in MCF7 and MDA-MB231 cells respectively. However, PARP1’s correlation with other
PTMs varied from no relationship to moderate negative correlation and differed across cell
lines (figshare [50]).
DNase 1 hypersensitive sites (DHSs) mark regulatory regions on DNA such as enhancers,
promoters, silencers, insulators and locus control [64]. In order to further define PARP1’s role
in gene regulation, we mapped the association of PARP1 binding to DHSs. DHS data in MCF7
and MDA-MB231 cells were obtained from the UCSC Genome Browser [46,47] and used to
correlate the relative enrichment of PARP1 within 1 kb regions surrounding the DHSs. We
found that the density of PARP1 nucleosome midpoints is much higher near DHSs (Fig 2B) in
both cell types.
PARP1 co-localizes with nucleosomes positioned at CTCF flanking
regions
Chromatin organization into distinct functional domains is important for the temporal and
spatial gene expression patterns required for proper development in the mammalian genome
[65]. One such chromatin organizer is CCCTC-binding factor (CTCF), a sequence-specific
transcription factor that binds to its target site and links chromosomal domains [66]. Thus
CTCF binding sites relate to gene regulatory regions. Indeed, earlier genome-wide analysis
studies identified well-positioned nucleosomes and DNase 1 hypersensitive sites as flanking
CTCF-binding sites [67]. Additionally, CTCF directly induces PARP1’s PARylation activity in
the absence of DNA damage, suggestive of an interaction between these two proteins in vivo
[68]. Thus, to further explore the functional binding of PARP1, we performed a genome-wide
characterization of its binding to CTCF binding sites. For this, we measured CTCF binding
sites in MCF7 cells [69] and used these to analyze PARP1 binding sites in both cell types. We
show that PARP1 binds to the nucleosomes flanking the CTCF binding sites in MCF7 cells
with Pearson correlation r = 0.2; p< 0.05 (Fig 3). We next asked if that is true for
MDA-MB231 as well. We simulated the CTCF binding sites from MCF7 onto MDA-MB231
Fig 2. PARP-1 is enriched at active epigenetic marks. (A) PARP1 associates with genomic regions containing specific histone modifications. Genomic
locations of various histone modifications were mapped on PARP-1 bound regions of the human genome. Solid green, red, blue, orange and black lines
represent PARP-1 alignment with H3K4me3, H3K36me3, H3K27ac, H3K27me3, and H3K9me3modifications in MCF7 and MDA-MB231 cells. (B) PARP1
also binds to DNase hypersensitive sites in both cell types.
doi:10.1371/journal.pone.0135410.g002
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cells. This was done with the assumption that CTCF binding sites are on DNA sequences
which do not change from cell type to cell type, though mindful of the fact that ~20% of CTCF
binding sites are cell-type specific [70]. Results from MDA-MB231 cells (Pearson correlation
r = 0.17; p< 0.05) recapitulated the results fromMCF7 cells (Fig 3). Since, CTCF PARylation
protects certain CTCF regions from DNAmethylation, underlining the importance of the
cross talk between PARP1, CTCF and DNAmethylation in the maintenance of nuclear organi-
zation [71]. In line with these studies, we next aimed to determine the relationship of PARP1
binding with DNA methylation status.
PARP1 binds to hypo-methylated DNA regions
DNAmethylation is one of several epigenetic mechanisms that cells use to control gene expres-
sion. Several studies show that methylation near gene promoters correlates with gene expres-
sion with more methylation of promoters correlating with low or no transcription [72].
Although earlier studies have implicated PARP1’s PARylation of DNAmethyltransferase 1
(DNMT1) in DNA demethylation, the functional association and gene regulatory function
remains poorly understood [71,73–75]. In an attempt to understand the interplay between
PARP1 and DNA methylation, we obtained genome-wide data of CpG methylation in both cell
types (GEO: GSM999373 for MCF7 and GSM699947 for MDA-MB231) and divided the meth-
ylation status into highly methylated (>10 reads) and less methylated (<10 reads). We then
mapped the presence of PARP1 within 250 bp regions of these methylation sites. Our results
show that PARP1 binding negatively correlates with the presence and completeness of DNA
methylation (Fig 4A)—the more methylated the region (>10), the less PARP1 binding was
observed at these regions. Conversely, the lower the level of methylation, the more PARP1
enrichment is observed (Fig 4A and 4B). While in mammals cytosines are predominantly
methylated in the context of the CpG dinucleotide, human cytosine methyltransferases also
recognizes CWG and CCWGG (where W stands for A or T) albeit at very low frequency [76].
We therefore analyzed the enrichment of PARP1 at these CWG regions. We divided the meth-
ylation status of these CWGs as before, with highly methylated regions being>10 reads and
less methylated being<10 reads. Here too, we observed that as the level of methylation
decreased, the amount of PARP1 binding increased (Fig 4A and 4B). The pattern followed
from highest to least PARP1 binding e.g. CWG1>CWG10>CG1>CG10.
The above analyses were done when both strands were methylated. We further tested the
enrichment of PARP1 when only one DNA strand is methylated (hemimethylation). Our anal-
yses at hemimethylated sites showed more PARP1 binding at hemimethylated sites compared
Fig 3. CTCF flanking regions overlap with PARP-1-associated nucleosomes. CTCF binding sites on
genome scale were mapped with genome-wide PARP-1 associated regions in breast cancer cells in MCF7
cells (blue) and MDA-MB231 cells (red). We quantified the correlation between PARP1 binding and CTCF
binding and showed a Pearson correlation r of about 0.18 (p < 0.05) in both cell types (figshare) [50]).
doi:10.1371/journal.pone.0135410.g003
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to homomethylated sites. These results are consistent with mutually exclusive binding of
PARP1 and DNA methylation status. Overall, the pattern of PARP1 binding from most to least
binding is as follows: hemi-CWG1> hemi-CpG1> hemi-CWG10> hemi-CpG10> homo-
CWG1> homo-CWG10> homo-CpG1> homo-CpG10 (Fig 4). Collectively, our findings
show that PARP1 binding is inversely correlated to the methylation status.
Functional context of PARP1-mediated differentially methylated sites in
the genome
Our data suggests that PARP1 is involved in eukaryotic DNA methylation in gene expression,
which is consistent with previous studies, concluding that PARP1 through PARylation of
DNMT1 determines the methylation pattern at specific promoters [71,75]. We next asked
whether PARP1 binding and DNA methylation pattern regulate each other globally. We
treated cells with either 5-aza-cytidine or decitabine (both DNA demethylating agents), and
measured the occupancy of PARP1 at specific promoters in MCF7 cells. We show that
Fig 4. Global analysis of PARP-1 association with methylated DNA.Genome-wide methylated CpG and non-CpG sites were aligned with PARP-
1-associated nucleosomal DNA sequences obtained from PARP1-nuc-ChIP-seq and showed mutually exclusive pattern between both signals. (A)
PARP1-binding at methylated sites of MCF7 cells (B) MDA-MB231 cells. CG-1 and CG-10 (blue and red) lines are PARP-1 association with moderately and
highly methylated sites respectively. CpG sites; CwG-1 and CwG-10 (green and violet) represent PARP1 presence at moderately and highly methylated non-
CpG sites (see methods). (C) PARP1 presence at hemi-methylated DNA in MCF7 cells and (D) in MDA-MB231 cells. CG-1 and CG-10 (blue and red lines)
indicate moderately and highly hemi-methylated sites while CwG-1 and CwG10 represent moderately and highly hemi-methylated non-CpG sites
respectively.
doi:10.1371/journal.pone.0135410.g004
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treatment resulted in an increase of PARP1 occupancy at certain promoters (S5A Fig), imply-
ing that there is interplay between PARP1 and methylation. We then looked at what happens
to the methylation status when PARylation is inhibited. Cells were treated with PARylation
inhibitor PJ34 and total methylation in cells was measured. Interestingly, we observed no sig-
nificant change in total methylation content between non-treated and PJ34-treated cells (S5B
and S5C Fig). We therefore hypothesize that changes in methylation pattern must be genomic
region specific.
To determine the PARP1-mediated methylation regions, MCF7 cells were treated with
PJ34, the genomic DNA purified and subjected to the Infinium HumanMethylation450 Bead-
Chip microarray analyses. This microarray method allows the interrogation of 485,000 methyl-
ation sites per sample at single CpG site resolution [77,78]. After analyses, we detected
differential methylation in 1,201 CpG sites, of which 869 were hypermethylated and 333 were
hypomethylated (Fig 5A; S6 Fig, S2 and S3 Tables). These differentially methylated regions
were non-randomly distributed (Fig 5A and 5D) in relationship to gene annotations and CpG
density.
From the functional genome distribution standpoint (i.e. distribution promoter, gene body,
3’UTR and intergenic regions), we found that 641 (53.37%) differentially methylated sites were
located in promoters, while 243 sites (20.23%) were located in the gene body (Fig 5B and S2
and S3 Tables). In addition, 19 (1.58%) and 150 (12.48%) of these differentially methylated
sites were found at 3' untranslated regions and intergenic sequences, respectively (Fig 5B and
S7 Fig). From the CpG content and neighborhood context standpoint, we referred to: (i)
“islands” as a DNA sequence (>200 bp window) with a GC content>50% and an observed
CpG ratio of>0.6; (ii) “shores” as sequences 0–2 kb distant from the CpG island; (iii) “shelfs”
as sequences 2–4 kb distant from the CpG island; and (iv) “open sea/others” as the remaining
sequences (Fig 5C). Using these criteria, we determined that 661 or 55.04% of the differentially
methylated sites were in CpG islands, 280 (23.31%) were in CpG shores, 32 (2.66%) were in
CpG shelves and 229 (19.07%) were in the open sea (Fig 5C). Globally though, putting the
shores and the CpG islands together, PARP1-mediated differential methylation occurred pref-
erentially at these sites. These results highlight PARP1’s critical role in methylation at epigenet-
ically variable regions. Furthermore, most of these sites are at promoters, indicating a role for
PARP1 in regulating active transcription (Fig 5B). We did not observe any preference in the
chromosome with respect to the differential methylation patterns as the differential methylated
sites were distributed among all 22 autosomal chromosomes and one sex chromosome (data
not shown).
Gene Ontology analysis of PARP1-mediated hypo and hypermethylated
loci
A total of 869 genes were hypermethylated and 333 genes were hypomethylated in MCF7 cells
after treatment with PJ34 (Fig 6). We next asked whether these PARylation-mediated differen-
tial methylation patterns were linked to specific biological processes. By performing enrich-
ment analysis using Gene Ontology (GO) and KEGG pathways, we found that target genes of
PARylation-mediated methylation are involved in distinct cellular processes (S4 Table). In
addition, PARylation-mediated hypomethylated genes are involved in significant pathways
attributed to cancer related cell events, focal adhesion and spliceosome activities among others.
Conversely, hypermethylated genes are involved in pathways involved in adherens junctions,
ribosomes, nucleotide excision repair and homologous recombination (S4 Table). Interest-
ingly, 39 PARylation-methylation-mediated genes were both hypo- and hypermethylated
(Fig 6). We hypothesized that these could be differentially methylated at different genomic
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locations. Further analyses show this to be true (for example: PARylation- mediated hypo-
methylation of the promoter of PAK1P1 as well as hypermethylation to the gene body) (S4
Table). We show for the first time that inhibition of PARylation affects a large number of
methylation events at several CpGs of which the promoter regions were most affected.
Fig 5. PARP1-mediated differential methylation profile (after PARylation inhibition) according to: (A) all
differential methylated patterns as analyzed on the Infinium HumanMethylation450 BeadChip; (B) differential
methylated patterns are mapped to gene regions based on their functional genome distribution; (C) CpG
island regions based on CpG content and neighborhood context (TSS: proximal promoter, defined as 200 bp
or 1500 bp upstream of the transcription start site; UTR: untranslated region; CpG island: 200+ bp stretch of
DNA with a C+G content of >50% and an observed CpG/expected CpG in excess of 0.6; shore: the flanking
region of CpG islands, 0–2000 bp; shelf: regions flanking island shores (i.e., covering 2000–4000 bp distant
from the CpG island); on the HumanMethylation450 BeadChip (two biological replicates of non-treated and
PARylation inhibited samples were used).
doi:10.1371/journal.pone.0135410.g005
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Validation of microarray differential methylation analyses
We used methylation-sensitive restriction enzyme digestion PCR (MSRE-PCR) [79] with
gene-promoter-specific primers to validate the changes in methylation pattern in response to
PARylation inhibition. This method fingerprints the methylation patterns by using methyla-
tion-sensitive restriction enzymes. First, we normalized the length of genomic DNA fragments,
used for MSRE-PCR by digesting DNA with HindIII restriction enzyme. Then, these DNA
samples were further digested withHpaII (CCGG site) and HhaI (GCGC site) restriction
enzymes, which are inhibited by the methylation of the internal cytosine. Samples were then
subjected to PCR amplification, which will only occur when the sites are methylated, and there-
fore uncut by the two methylation sensitive enzymes. Our analyses show that at the promoter
of ZNF140 there is very little methylation in NT cells, but with PJ34 treatment we observed an
increase in methylation, as indicated by increase in PCR amplification (Fig 7). A similar
Fig 6. Venn diagram analyses of genes with differential methylation patterns after PARylation
inhibition. These analyses show that some genes are commonly modulated by PARylation inhibition.
Interestingly, most of them are differentially modified at different genomic regions of the gene. For instance a
particular gene is hypermethylated at the promoter region while it is hypomethylated within the gene body.
The function of such differential patterns remains to be elucidated.
doi:10.1371/journal.pone.0135410.g006
Fig 7. Validation of differential methylated regionsmediated by PARylation using MSRE-PCR results
on selected genes.Methylation-specific PCR (MSP) assay of three genes in MCF-7 cells (duplicate
reactions for each gene). Primers for various genes in NT and PJ34-treated cells at corresponding CpG
islands were used. Three biological replicates of samples were used.
doi:10.1371/journal.pone.0135410.g007
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pattern was observed at the BPAP (BRAC1-associating protein) promoter. Meanwhile at the
TROVE2 promoter in NT cells, while the HpaII site is unmethylated, the HhaI site is methyl-
ated. Interestingly, treatment with PJ34 showed a reversal of the methylation pattern at these
restriction enzyme sites. All these results are consistent with the microarray analyses. However
at the PLAU promoter, MSRE-PCR analyses showed no change in methylation pattern, though
our microarray analyses show hypomethylation after PJ34 treatment. We attribute these differ-
ences as due to the lower resolution accorded by MSPCR analyses compared to the microarray
analyses (Fig 7). Finally, since PJ34 is a broad based PARP inhibitor, we verified that the
changes in methylation involve PARylation, by using a second PARP inhibitor DPQ. Inhibition
of PARylation with DPQ and subsequent MSRE-PCR, showed a similar trend in methylation
patterns as with PJ34 (S8 Fig).
Discussion
Though earlier studies have shown PARP1 involvement in chromatin remodeling, transcrip-
tion activation and repression, a consensus among these functions remains poorly understood.
PARP1 spatial localization on the human genome landscape provides extremely valuable
insights for understanding how PARP1 coordinates maintenance of chromatin architecture
with gene expression regulatory networks. Several studies have demonstrated that nucleosome
free regions at TSS aid in promoter accessibility to pre-transcription initiation complexes that
are required for transcription initiation [80]. We found PARP1 enriched at TSS of actively
transcribed gene promoters in both MCF7 and MDA-MB231 breast cancer cell lines. In con-
trast, most of the transcriptionally repressed gene promoters were devoid of PARP1. Moreover,
Gene Ontology analyses strongly indicate that PARP1 binds at TSSs of genes involved in meta-
bolic processes, developmental processes, cell communication and compartmentalization (data
not shown). These results suggest that PARP1 is a global regulator of eukaryotic gene
expression.
Gene regulatory regions are characterized by specific histone marks. H3K4me3 and
H3K36me3 associate with active promoters and gene bodies respectively [81,82], while
H3K27ac differentiate active and poised enhancers [83]. Likewise, H3K9me3 and H3K27me3
have been implicated in repressive chromatin domain formation and gene silencing [84–86].
Our observations of the correlatively binding of PARP1 at regions bound by H3K36me3 and
H3K4me3 and its absence at H3K9me3 and H3K27me3 sites is consistent with the idea of the
involvement of PARP1 in active chromatin-mediated gene regulatory processes corroborating
other studies [87]. While both cell lines exhibited similar association of PARP1 and H3K4me3,
the differential association of PARP1 and regions enriched by the other histone marks espe-
cially, H3K36me3 and H3K27me3 in these cells might be biologically relevant (Fig 2A). We
posit that these differences might suggest a functional cell type specific activity that requires
further studies to decipher.
DHS and CTCF sites also characterize regulatory regions. Our comparative studies reveal
that PARP1 binds to DHSs, as well as regions bound by CTCF both in MCF7 and MB231 cells
(Fig 2B and Fig 3), further supporting a role of PARP1 in gene regulation. Since PARP1 binds
to regions of active chromatin marks, it is not surprising that it associates with DHSs. Interest-
ingly though, the binding of PARP1 to CTCF sites is consistent with previous studies showing
that PARP1 forms a complex with CTCF to modulate DNA methylation [71]. Furthermore, it
was shown that CTCF-dependent PARP1 automodification and the PARylation of DNMT1 to
inhibit its methylation activity may be a possible mechanism for CTCF insulator activity
[88,89]. Hence, our correlative studies of genome-wide CTCF and PARP1 binding support the
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notion that these two factors act together in gene regulation and supports PARP1’s insulator
function.
Since earlier studies suggested that PARP1 also PARylates DNMT1 to inhibit DNAmethyl-
ation, we probed PARP1 binding at CpG sites [73–75]. Our results show that chromatin bind-
ing by PARP1 and DNAmethylation are mutually exclusive. Conversely highly methylated
regions have very stable nucleosomes (S9 Fig), which is in concert with previous studies
[90,91]. These results may imply that PARP1 or PARylation is involved in a process that stabi-
lizes a non-methylated chromatin region, though a direct test is needed. On the other hand,
PARylation has been shown to affect DNMT1 activity [75]. In line with this finding, our data
show that after inhibition of PARylation a substantial number of genes were hypermethylated.
However, we also observed hypomethylation at other genes. Our data reveal that a balance in
methylation globally is important, but also that the interplay between PARP1 and DNA meth-
ylation is more complex than just its removal of PARylated DNMT1. Since aberrant changes in
DNAmethylation have been widely reported in cancer, our data on PARP1’s involvement in
DNAmethylation provides a platform to further elucidate its effect in gene regulation both in
normal and in disease states. A comparison of PARP1-bound nucleosomes to total nucleo-
somes (MNase-seq) shows that PARP1 binds to a subset of nucleosomes (S9 Fig). It is possible
that these PARP1 bound chromatin regions are more labile and therefore subject to removal,
but this still needs to be tested.
Conclusion
Overall, our findings suggest that PARP1 binds active gene regulatory regions both in
MDA-MB231 and MCF7 cells (S10 Fig). PARP1’s absence at methylated DNA and repressive
histone marks, and enrichment at active histone modifications and DNase hypersensitive sites
indicate that PARP1 communicates with gene expression regulatory networks. Moreover,
PARP1 association with CTCF-binding regions indicates involvement in maintenance of chro-
matin architecture. Finally, the interplay between PARP1’s presence and DNA methylation
pattern provides a platform for future studies into the functionality of this interplay and its role
in epigenetic regulation in the cell.
Supporting Information
S1 Fig. Reproducibility of PARP-nuc-ChIP-seq data analyses. Using both methods of
PARP1 peak calling methods showed high reproducibility with each replicate. (A) Peak detec-
tion was performed by running model-based analysis of ChIPSeq (MACS) bandwidth of 200
bp, and a P-value threshold of 1 × 10−5). (B) Aligning PARP1-nucleosome reads and mapping
the centers of these nucleosomes showed reproducibility with each replicate. (C) Wig plots
imported into the UCSC browser show reproducibility of the peaks.
(PDF)
S2 Fig. ChIP assay and validation.Nuclei from MCF7 and MDA-MB231 cells were formalde-
hyde-fixed and chromatin MNase digested to yield< 450 bp fragments. Chromatin was sub-
jected to ChIP using PARP1 antibody. (A) Western blot analyses of PARP1 association with
the eluted ChIP experiment, validating the presence of PARP1. (B) Resultant DNA fragments
elution steps were purified and analyzed on 3% NusieveTM agarose gel electrophoresis. DNA
mononucleosomal fragment (arrow) from elution step was excised and subjected to Illumina
sequencing.
(PDF)
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S3 Fig. PARP1 binding at specific promoters correlate with active gene transcription.We
created wiggle files from the PARP1 nuc-ChIP-seq signals and aligned them to the human
genome using UCSC genome browser (hg19). PARP1 binding sites in (A) MCF7 and
MDA-MB231 in IGFBP7 and (B) IGFBP6 promoters and gene bodies respectively (represented
by lines). Measurement of PARP1 occupancy, using quantitative real-time PCR at promoters
of (C) IGFBP7 and (D) IGFBP6 respectively. (E) Gene expression profile of IGFBP7 and
IGFBP6 as shown in MCF7 and MDA-MB231 obtained from the GSEA (Broad Institute).
Blue bars indicate regions we called based on significance as PARP1-nucleosomes bound.
(PDF)
S4 Fig. Evaluation of siRNA transfection efficiency in MCF7 cells. The effects of two PARP1
siRNAs—PARP1-siRNA1 and PARP1-siRNA2, targeting different regions of PARP1 gene on
the levels of PARP1 were analyzed by western blot (transfection was performed at 50 nmol/L
PARP1 siRNA (Dharmacon) for 48 h). Unrelated siRNA (LacZ) served as negative control. (A)
Representative western blot analyses (B) Band intensities were quantified and measured as the
percentage over β-actin, normalized to non-treated cells. (C) Representative agarose gel images
stained with Gelstar (inverted) of PCR analyses showing the measurement of PARP1 occu-
pancy at PARP1-target genes after PARP1-knockdown. The occupancy of PARP1 at a previ-
ously validated promoter (ITPR1 –ref. 29) was used as positive control D) PARP1 occupancy
from quantitative real-time PCR analyses at the same PARP1-target genes as in C. Data are
expressed as the mean ± S.E.M, n = 3.  P< 0.001 compared to the control group by student
t-test. (PARP1 occupancy in wild-type cells (treated with LacZ) was normalized to 1 and all
other measurements of relative PARP1 occupancy in the various treatments were measured
relative to PARP1 occupancy in wild-type cells).
(PDF)
S5 Fig. Measurement of PARP1 occupancy and activity after 5-aza-cytidine, decitabine and
PJ34 treatment. (A) Measurement of PARP1 occupancy at selected promoters after inhibition
of methylation using 5-aza-cytidine. (B) Treatment of cells with PJ34 did not change the global
percentage of 5-methylcytosine levels in MCF7 and MB-MDA231 cells. (C) Treatment of cells
with PJ34, resulted in reduction in PARylation as measured using the Zymo EZ-96DNAMeth-
ylation Kit (Catalog #D5004).
(PDF)
S6 Fig. Differential methylated pattern analyses analyzed from the Infiniummicroarray
analyses. Scatter plot of log2 (fold_change) of the 1,202 sites illustrating differences in DNA
methylation between control and PJ34-treated (PARylation inhibited) cells. A total of 1,202
CpG Sites with abs(log2(fold_change))> 1 were observed.
(PDF)
S7 Fig. PARylation-mediated methylation patterns in MCF7 cells. Genomic distribution of
hypomethylated and hypermethylated according to gene regulatory regions after inhibition of
PARylation.
(PDF)
S8 Fig. MSRPE PCR on DPQ treated DNA. Results form PARP1 target genes shown in Fig 7
were also validated using a second PARP1-inhibitor (DPQ).
(PDF)
S9 Fig. Comparison of MNase-seq data (total nucleosome positioning) with PARP1-bound
nucleosomes at (A) TSSs (B) CTCF binding sites (C) highly DNAmethylated sites.
(PDF)
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S10 Fig. A view of PARP1 correlative binding with several gene regulatory features. PARP1
chromatin features in MCF7 cells are displayed for a 30 kb region in the AAAS and SP7 locus
from UCSC gene annotations. Shown also are total nucleosomes (MNase-seq) fromMCF7
cells, used as input. Checkered boxes indicate nucleosomal regions not bound by PARP1. The
PARP1-nucleosome- binding sites are shown (1); the gene structure of the genes with this
region are shown (2); green bars indicate the CpG islands; 3. Also shown are the DNase hyper-
sensitive sites (4); blue bars show regulatory regions and lastly (6) known CTCF sites.
(PDF)
S1 Table. Pearson correlations and p values of PARP1 and regulation regions genome-wide
and at TSSs.
(PDF)
S2 Table. Hypermethylated genes and genomic regions mediated by PARylation inhibition.
(PDF)
S3 Table. Hypomethylated genes and genomic regions mediated by PARylation inhibition.
(PDF)
S4 Table. Pathways of gene targeted by PARylation-mediated methylation.
(PDF)
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